|Min SIP Amount||Not Supported|
|NAV||₹8.84 (02 Jul 2020)|
|Fund Started||19 Feb 2018|
|Fund Size||₹78 Cr|
|Abbott India Ltd.||Healthcare||Equity||5.1%|
|PI Industries Ltd.||Chemicals||Equity||4.6%|
|Ajanta Pharma Ltd.||Healthcare||Equity||3.9%|
|Navin Fluorine International Ltd.||Chemicals||Equity||3.8%|
|Ipca Laboratories Ltd.||Healthcare||Equity||3.7%|
|HDFC Bank Ltd.||Financial||Equity||3.7%|
|Astral Poly Technik Ltd.||Chemicals||Equity||3.2%|
|Alkem Laboratories Ltd.||Healthcare||Equity||3.2%|
BOI AXA Midcap Tax Fund Series 1 Direct Growth is a Equity Mutual Fund Scheme launched by BOI AXA Mutual Fund. This scheme was made available to investors on 19 Feb 2018. Alok Singh is the Current Fund Manager of BOI AXA Midcap Tax Fund Series 1 Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹78 Cr and the Latest NAV as of 02 Jul 2020 is ₹8.84.
The BOI AXA Midcap Tax Fund Series 1 Direct Growth is rated Moderately High risk.
The scheme seeks to generate capital appreciation over a period of ten years by investing predominantly in equity and equity-related securities of midcap companies along with income tax benefit.